Disease · MONDO_0018044
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| JZP-258 vs Placebo: Percentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc) | 12 of 56 | 52 of 59 | 115 | NCT03533114 | Trial comparisons |
| JZP-258 vs Placebo: Percentage of Participants Reported as Worse on the Clinical Global Impression of Change (CGIc) | 12 of 56 | 52 of 59 | 115 | NCT03533114 | Trial comparisons |
| TAK-925 112 mg vs Placebo: deaths from any cause | 0 of 25 | 0 of 27 | 52 | NCT04091438 | Trial comparisons |
| TAK-925 112 mg vs Placebo: serious adverse events | 0 of 25 | 0 of 27 | 52 | NCT04091438 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: deaths from any cause | 0 of 22 | 0 of 22 | 44 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: serious adverse events | 1 of 22 | 0 of 22 | 44 | NCT03772314 | Trial comparisons |
| Clarithromycin vs Placebo: serious adverse events | 0 of 22 | 0 of 20 | 42 | NCT01146600 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Much or Very Much Improvement From Baseline on Patient Global Impression of Change (PGIC) for Sleepiness Score | 14 of 22 | 10 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Much or Very Much Improvement by Patient Global Impression of Change (PGIC) for Overall Disease Severity Score | 13 of 22 | 10 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Much or Very Much Improvement With Patient Global Impression of Change (PGIC) for Cognitive Dysfunction Score | 5 of 22 | 10 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Much or Very Much Improvement by Patient Global Impression of Change (PGIC) for Sleep Inertia Score | 4 of 22 | 4 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Any Improvement With Patient Global Impression of Change (PGIC) for Cognitive Dysfunction Score | 16 of 22 | 13 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Any Improvement by Patient Global Impression of Change (PGIC) for Overall Disease Severity Score | 18 of 22 | 16 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Any Improvement by Patient Global Impression of Change (PGIC) for Sleep Inertia Score | 11 of 22 | 11 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Any Improvement From Baseline on Patient Global Impression of Change (PGIC) for Sleepiness Score | 19 of 22 | 16 of 20 | 42 | NCT03772314 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018044/comparisons